In this article, we will discuss Siltuximab (Dosage Overview). So, let’s get started.
Siltuximab is indicated for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Limitation of Use
Siltuximab was not studied in patients with MCD who are HIV positive or HHV-8 positive because Siltuximab did not bind to virally produced IL-6 in a nonclinical study.
Siltuximab 11 mg/kg is given over 1 hour as an intravenous infusion administered every 3 weeks until treatment failure.
Perform hematology laboratory tests prior to each dose of Siltuximab therapy for the first 12 months and every 3 dosing cycles thereafter.
Do not administer Siltuximab to patients with severe infections until the infection resolves.
Discontinue Siltuximab in patients with severe infusion related reactions, anaphylaxis, severe allergic reactions, or cytokine release syndromes. Do not reinstitute treatment.